By DoM Communications | Date published: May 19, 2025
Kriti Mittal to Study Safety and Tolerability of Relugolix in Combination with Abiraterone or Apalutamide for Treatment of Patients with Advanced Prostate Cancer
In a recent study published in Targeted Oncology, Kriti Mittal, MD, MS, assistant professor of medicine and director of the GU Medical Oncology program in the Division of Hematology/Oncology, assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of relugolix in combination with androgen receptor signaling inhibitors (ARSIs) in patients with advanced prostate cancer (aPC).